Celldex Therapeutics
69
6
13
36
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
24.6%
17 terminated/withdrawn out of 69 trials
67.9%
-18.6% vs industry average
7%
5 trials in Phase 3/4
33%
12 of 36 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (69)
A Study of Barzolvolimab in Patients With Atopic Dermatitis
Role: lead
A Phase I Study of CDX-622
Role: lead
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Role: lead
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
Role: lead
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Role: collaborator
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Role: collaborator
A Study of CDX-622 in Participants With Mild to Moderate Asthma
Role: lead
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
Role: lead
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Role: collaborator
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Role: lead
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
Role: lead
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Role: collaborator
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Role: collaborator
A Study of Barzolvolimab in Patients With Prurigo Nodularis
Role: lead
Converting HR+ Breast Cancer Into an Individualized Vaccine
Role: collaborator
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
Role: lead
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Role: collaborator
A Study of CDX-585 in Patients With Advanced Malignancies
Role: lead
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Role: collaborator
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Role: lead